Cite
HARVARD Citation
D'Antoni, M. et al. (2022). Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials. Journal of acquired immune deficiency syndromes. pp. 433-440. [Online].